Real-world experience of pembrolizumab in microsatellite instability-high CRC: A Scottish multicenter analysis. Journal of Clinical Oncology

Medicine & Life Sciences

• pembrolizumab 100%
• Microsatellite Instability 87%
• Medical Oncology 84%
• immune no. 2 13%
• Disease Progression 8%
• Population 8%
• Scotland 6%
• National Health Programs 5%
• Contraindications 5%
• Patient Safety 5%
• Standard of Care 5%
• Treatment Failure 5%
• Duration of Therapy 5%
• Progression-Free Survival 4%
• Immunotherapy 4%
• Suspensions 4%
• Colorectal Neoplasms 4%
• Therapeutics 3%
• Clinical Trials 3%
• Demography 3%
• Mutation 3%
• Survival 3%
• Neoplasms 1%